NF2 and meningioma: Molecular characterizations based on genetic mutations (such as NF2, SMO, TERT promotor, and TRAF7) and methylation profiles (i.e., H3K27 trimethylation) are under development, aiming to refine the biological classification and to provide new insights into the prognosis and evolving landscape of targeted treatment for meningiomas [12–15].